‘Evolve’ Study Will Assess Safety and Tolerability of Unique Anti-Cancer Agent, ColoAd1 OXFORD, UK – 26 September 2012 – PsiOxus Therapeutics, Ltd. (PsiOxus) has treated the first patient in its phase I/II clinical trial of ColoAd1 for the treatment of metastatic solid tumours. The Evolve (EValuating OncoLytic Vaccine Efficacy) study is the first clinical trial
LONDON – 13 September 2012 – PsiOxus Therapeutics, Ltd. (PsiOxus) today announced the conversion of almost £1 million ($1.5 million) of loan notes from the Wellcome Trust, a leading global charitable foundation. The loan conversion follows a Series B round of equity financing totaling £22 million ($34 million) closed in July 2012. The loan notes
OBN 2012 Annual Awards recognise PsiOxus for £22 Million ($34 Million) in Series B Financing to Drive Clinical Development for Oncolytic Vaccine. Mercia Fund Management MD Mark Payton attended the OBN 2012 Annual Awards Dinner last night and is delighted to announce that PsiOxus Therapeutics, Ltd. (PsiOxus) won the Best Biotech Fund Raiser award. PsiOxus
London/Moscow, 10th September 2012 – Pro Bono Bio Group plc (“PBB”), the international healthcare group, and PolyTherics Limited (“PolyTherics”), a provider of solutions for the development of better biopharmaceuticals, announce further progress on their haematology alliance to produce longer-acting versions of blood factor proteins. Following an agreement between the parties in May 2012, PBB and
Founded in a hot bed of fresh thinking and unique ideas, university spin-outs are becoming increasingly popular with both savvy investors, who can achieve a healthy return, and universities benefitting from funding channelled back into their R&D and facilities. Working with eight Midlands’ universities, Mercia Fund Management has supported spin-outs from seed to successful exit
PRESS RELEASE London, UK, 20 August 2012 ? PolyTherics Limited (“PolyTherics”), a provider of solutions to enable the development of better biopharmaceuticals, is very pleased to announce the appointment of Dr Georg Buchner as Vice President of Business Development. Georg will work with Jenny Filbey, PolyTherics’ business development representative in the USA and CEO John
Birmingham/Oxford, 20 July 2012. Mercia Fund Management has launched the Mercia Growth Fund capitalising on the recent introduction of Seed EIS (SEIS) and the marked enhancements to EIS in the Finance Act. Mercia Fund Management believes a hybrid fund will provide investors with a combination of maximised tax efficiency and the flexibility to invest in
PRESS RELEASE FOR IMMEDIATE RELEASE PolyTherics granted further patents for TheraPEG™ and GlycoPol™ POLYTHERICS EXPANDS THE COVERAGE OF ITS PATENTS IN MAJOR MARKETS London, UK, 18th June 2012 – PolyTherics Limited (“PolyTherics”), a provider of solutions to enable the development of better biopharmaceuticals, has strengthened its intellectual property estate with the granting of further patents
Champaign, Illinois, 2012-05-14 – The Blue Waters project is now well underway with a completion date of Fall 2012. As one of the most powerful supercomputers in the world, its immense computational power and stability will allow scientists to make breakthroughs in a diverse range of fields. Allinea DDT is the debugger they call on
Pro Bono Bio and PolyTherics progress and expand their relationship for the development of improved blood factors London, UK, 29 May 2012 – Pro Bono Bio Group plc (“PBB”), the international healthcare group, and PolyTherics Limited (“PolyTherics”), a provider of solutions for the development of better biopharmaceuticals, announce progress on their haematology alliance to produce